Related Experiment Video
Updated: Nov 1, 2025

Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapeutic Strategy for Acute Kidney Injury
Jia-Kun Li1, Cheng Yang2, Ying Su1
1Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Insights
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) show promise for treating acute kidney injury (AKI). MSC-EVs offer advantages over MSCs, including lower immunogenicity and easier storage, for potential AKI therapies.
Area of Science:
- Nephrology
- Regenerative Medicine
- Biotechnology
Background:
- Acute kidney injury (AKI) affects 10-15% of hospitalizations and 50% of ICU patients.
- Severe AKI can progress to chronic kidney disease or end-stage renal disease.
- Current AKI treatments are primarily supportive, necessitating more effective therapies.
Purpose of the Study:
- To review the therapeutic mechanisms of Mesenchymal Stem Cells (MSCs) and MSC-derived Extracellular Vesicles (MSC-EVs) in AKI.
- To explore recent advancements in enhancing MSC-EV efficacy for AKI treatment.
- To analyze the potential and limitations of EVs for AKI therapy.
Main Methods:
- Literature review of MSCs and MSC-EVs in AKI.
- Analysis of therapeutic mechanisms and recent research findings.
- Evaluation of the potential and limitations of EV-based therapies.
Main Results:
- MSCs are promising for cellular therapy due to ease of harvesting and low immunogenicity.
- Therapeutic effects of MSCs are mainly mediated by MSC-EVs.
- MSC-EVs offer advantages over MSCs, including lower immunogenicity, easier storage, and no tumorigenesis.
Conclusions:
- MSC-EVs represent a promising therapeutic strategy for AKI.
- Further research and clinical trials are needed to optimize MSC-EV efficacy and application.
- MSC-EVs have significant potential for the clinical treatment of AKI.
Abstract:
Acute kidney injury (AKI) is a common and potential life-threatening disease in patients admitted to hospital, affecting 10%-15% of all hospitalizations and around 50% of patients in the intensive care unit. Severe, recurrent, and uncontrolled AKI may progress to chronic kidney disease or end-stage renal disease. AKI thus requires more efficient, specific therapies, rather than just supportive therapy. Mesenchymal stem cells (MSCs) are considered to be promising cells for cellular therapy because of their ease of harvesting, low immunogenicity, and ability to expand in vitro. Recent research indicated that the main therapeutic effects of MSCs were mediated by MSC-derived extracellular vesicles (MSC-EVs). Furthermore, compared with MSCs, MSC-EVs have lower immunogenicity, easier storage, no tumorigenesis, and the potential to be artificially modified. We reviewed the therapeutic mechanism of MSCs and MSC-EVs in AKI, and considered recent research on how to improve the efficacy of MSC-EVs in AKI. We also summarized and analyzed the potential and limitations of EVs for the treatment of AKI to provide ideas for future clinical trials and the clinical application of MSC-EVs in AKI.
Related Concept Videos
Mesenchymal Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Acute Kidney Injury II: Pathophysiology

